Champions Oncology (NASDAQ:CSBR) This fall 2025 Earnings Name July 23, 2025 4:30 PM ET
Firm Contributors
David Barry Miller – Chief Monetary Officer
Ronnie Morris – CEO & Director
Convention Name Contributors
Matthew Gregory Hewitt – Craig-Hallum Capital Group LLC, Analysis Division
Operator
Greetings. Welcome to the Champions Oncology Fourth Quarter Fiscal Yr 2025 Earnings Name. (Operator Directions) Please observe this convention is being recorded.
I’ll now flip the convention over to your host, Ronnie Morris, Chief Government Officer. You might start.
Ronnie Morris
Good afternoon. I am Ronnie Morris, CEO of Champions Oncology. Becoming a member of me right this moment is David Miller, our Chief Monetary Officer. Thanks for becoming a member of us for our quarterly earnings name. Earlier than I start, I’ll remind you that we’ll be making forward-looking statements throughout right this moment’s name and that precise outcomes might differ materially from these indicated.
Further info on our threat elements may be present in our Type 10-Q and Type 10-Okay filings. A reconciliation of non-GAAP monetary measures to GAAP monetary measures is on the market in our earnings launch. Trying again, fiscal 2025 could finally be seen as a pivotal yr for Champions Oncology when marked by renewed momentum, strategic execution and foundational progress. Following a difficult fiscal 2024, we efficiently reestablished income progress and returned to profitability.
A spotlight of the yr was closing our inaugural information licensing deal within the third quarter, adopted by a number of smaller transactions within the latest quarter in addition to a rising pipeline exhibiting clear validation of our long-term imaginative and prescient and strategic route. Our core companies enterprise continues to be the inspiration of Champions Oncology. Constructed on our industry-leading PDX financial institution and its intensive multi-omic characterization, our platform stays a essential useful resource for pharmacology research throughout the biopharma sector.
Now we have made focused investments to strengthen our workforce and streamline